ADVISORY, April 01, 2016 --
What:
Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN), a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions, will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Robert Landry, Senior Vice President and Chief Financial Officer, will ring the Opening Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:
Monday, April 4, 2016 – 9:15 a.m. to 9:30 a.m. ET
Regeneron Media Contact:
Alexandra Bowie
(914) 847-3407
[email protected]
Nasdaq MarketSite:
Emily Pan
(646) 441-5120
[email protected]
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram Page:
http://instagram.com/nasdaq
For livestream of ceremonies and events visit our YouTube Page:
http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter page at:
http://twitter.com/nasdaq
For exciting viral content and ceremony photos visit our Tumblr Page:
http://nasdaq.tumblr.com/
Webcast:
A LiveStream of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice.
About Regeneron Pharmaceuticals, Inc.
Regeneron (Nasdaq:REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for high LDL cholesterol, eye diseases, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain, and infectious diseases. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
About NASDAQ-100 Index®
The NASDAQ-100 Index, launched in January 1985, is one of the most widely followed benchmarks in the world. The NASDAQ-100 Index is the basis of the PowerShares QQQ Trust (Nasdaq:QQQ) which aims to provide investment results that, before expenses, correspond with the NASDAQ-100 Index's performance. In addition, options, futures and structured products based on the NASDAQ-100 Index and the PowerShares QQQ Trust trade on various exchanges.
About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of approximately $9.6 trillion and nearly 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.
-NDAQA-


Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Italy Fines Apple €98.6 Million Over App Store Dominance
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 



